Hidden fungal threat in COVID-19 ICU patients revealed
NCT ID NCT04818853
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitored 219 adults with severe COVID-19 who needed a ventilator for at least 72 hours. Researchers checked for serious fungal infections, especially aspergillosis, using standard diagnostic methods. The goal was to learn how common these infections are and what puts patients at risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better detect and prevent dangerous fungal infections in severely ill COVID-19 patients.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may not apply to all COVID-19 patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
- Can a 15-Minute chat at a testing site boost COVID-19 vaccination?
- E-Ink screens in ERs could boost patient satisfaction
- Massive study tracks how lockdowns shaped mental health across america